Latest Cell Therapy News

Page 4 of 17
AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.
Ada Torres
Ada Torres
29 July 2026
Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.
Ada Torres
Ada Torres
27 July 2026
Arovella Therapeutics secured ethics approval and manufactured its first clinical batch of ALA-101, targeting blood cancers, while progressing its solid tumour program and refining autoimmune strategies. The company ended the quarter with $14.4 million in cash, supporting imminent clinical milestones.
Ada Torres
Ada Torres
27 July 2026
Imugene's azer-cel therapy shows a third patient response in the BTKi combination cohort of its Phase 1b trial, while CEO Leslie Chong steps down after nearly 11 years, prompting a leadership search.
Ada Torres
Ada Torres
27 July 2026
Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.
Ada Torres
Ada Torres
16 July 2026
Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.
Ada Torres
Ada Torres
14 July 2026
Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.
Ada Torres
Ada Torres
10 July 2026
Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.
Ada Torres
Ada Torres
1 July 2026
Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.
Ada Torres
Ada Torres
1 July 2026
AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.
Ada Torres
Ada Torres
1 July 2026
Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.
Ada Torres
Ada Torres
1 July 2026
Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.
Ada Torres
Ada Torres
30 June 2026

Browse the archive

Full archive